{"id":416689,"date":"2021-01-19T08:16:21","date_gmt":"2021-01-19T13:16:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416689"},"modified":"2021-01-19T08:16:21","modified_gmt":"2021-01-19T13:16:21","slug":"silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/","title":{"rendered":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW JERSEY , Jan.  19, 2021  (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the <em>\u201cInvesting in Psychedelics Series: Building Value Through IP\u201d <\/em>virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&amp;A session.<\/p>\n<p align=\"justify\">For more information and to register for this free conference, please visit the conference website at \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hpn6yE0nBj9ONNiLep7wYp201mcpThrSNopSlUzOJfu3pHccXW2U28QxcHpAGQ_WT-OBRkCnGUVCoxjnyP9PRR_Zjtq3Pkdm0V94emWfbi2PWtHRhsULuIF_yo1ps1ozadJn3NB12G_PDzudFGpyJMLhgmFGrlKSaM5DT4UOTIBsLg9vUWcu6TiqE7tm4qZYd3DXlFsM3rC1PQekWzUr15LrvE4Td76AZenq9qHfI2AezK3L1IKfA3erq7X4yt1YDQkE42rfNttqbYpNfY9V-r4IBH6KSHSt58bnDyf2UIaXJpCrhlPpPRsm3AhC0wgMXy_TnzrQgo1Aa3fbEmQSs6DpPN7BkcPEMF5XOpWijOLbtBV0-xJj3cDZzgBJqFjCiSKdy3-a0bRZJvkdH2d3JMOGmndvjr_LrmmAXBij63P1vqAujbzURiaUkcRoL32bBt-egOu-1ZDSVKODGZrgULKnbsDwFWcld-_Zz6jrrTw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/promo.cfnmedia.com<\/u><\/a> or contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g6RTaF4Zva29xGOZtBHi1ZQ052N0f4m0md53SdRAr3QaL58pXlbQjyjtLua-zUKazZef70xlvnOIETscxIAoxEOO88kY2z80wkXKeDgtPi4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>brett@haydenir.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>About \u2018Investing in Psychedelics\u2019 Conference<\/strong>\n      <\/p>\n<p align=\"justify\">The virtual conference will feature live panels with moderators. Panel participants will consist of company executives, IP specialists, and bankers across three sessions. Attendees will be able to submit questions to the panelists via the moderators. Company executives will be interviewed ahead of the live event and the recorded videos will be shared with conference registrants.<\/p>\n<p>\n        <strong>About Silo Pharma <\/strong>\n      <\/p>\n<p align=\"justify\">Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.\u00a0 For more information, visit <u>www.silopharma.com<\/u>. <\/p>\n<p align=\"justify\">\n        <b><br \/>\n          <u><br \/>\n            <b>Investor Relations Contact<\/b><br \/>\n          <\/u><br \/>\n          <b>:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b><br \/>\n        <\/b>\n      <\/p>\n<p align=\"justify\">\n        <b><br \/>\n          <b>Hayden IR<\/b><br \/>\n        <\/b>\n      <\/p>\n<p>Brett Maas<br \/>646-536-7331<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g6RTaF4Zva29xGOZtBHi1aVcZ5uhbn3vLOb15Xp-YQaUQ_z6_eVJBe0ujY929qmGPK894lfPURGCCEsP9_bCUMyoSKDj0Jt8A5M5ZieEPtU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>brett@haydenir.com<\/u><\/a>\u00a0\u00a0<\/p>\n<\/p>\n<p>\n        \n      <\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/cb1f27c0-d398-4d47-b60a-826f4d55963a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the \u201cInvesting in Psychedelics Series: Building Value Through IP\u201d virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&amp;A session. For more information and to register for this free conference, please visit the conference website at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416689","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the \u201cInvesting in Psychedelics Series: Building Value Through IP\u201d virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&amp;A session. For more information and to register for this free conference, please visit the conference website at &hellip; Continue reading &quot;Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T13:16:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics\",\"datePublished\":\"2021-01-19T13:16:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/\",\"name\":\"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\",\"datePublished\":\"2021-01-19T13:16:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk","og_description":"NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the \u201cInvesting in Psychedelics Series: Building Value Through IP\u201d virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&amp;A session. For more information and to register for this free conference, please visit the conference website at &hellip; Continue reading \"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T13:16:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics","datePublished":"2021-01-19T13:16:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/","name":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==","datePublished":"2021-01-19T13:16:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODAwNiMzOTM1MTUzIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416689"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416689\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}